Lymphadenopathy secondary to lamotrigine (Lamictal).
We report lymphadenopathy in a 5-yo-female most likely secondary to lamotrigine. Lamotrigine is effective in the treatment of partial and generalized seizure disorders and often prescribed by neurologists and pediatricians because of its effectiveness in children with idiopathic, resistant generalized seizure disorders; it lacks cognitive impairment. Lamotrigine's chemical structure contains an aromatic ring and is similar to phenytoin, carbamazepine and phenobarbital. The patient had a documented drug allergy to both phenytoin and carbamazepine, and clinically improved following discontinuation of the lamotrigine. Clinicians should be aware of this potential adverse event for patients treated with lamotrigine.
D000927:Anticonvulsants / Q000009:adverse effects*; D002675:Child, Preschool; D005260:Female; D006801:Humans; D000077213:Lamotrigine; D008206:Lymphatic Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D014227:Triazines / Q000009:adverse effects*
D000927:Anticonvulsants; D014227:Triazines; D000077213:Lamotrigine